Bojana Jovanović, Daniel Temko, Laura E Stevens, Marco Seehawer, Anne Fassl, Katherine Murphy, Jayati Anand, Kodie Garza, Anushree Gulvady, Xintao Qiu, Nicholas W Harper, Veerle W Daniels, Huang Xiao-Yun, Jennifer Y Ge, Maša Alečković, Jason Pyrdol, Kunihiko Hinohara, Shawn B Egri, Malvina Papanastasiou, Raga Vadhi, Alba Font-Tello, Robert Witwicki, Guillermo Peluffo, Anne Trinh, Shaokun Shu, Benedetto Diciaccio, Muhammad B Ekram, Ashim Subedee, Zachary T Herbert, Kai W Wucherpfennig, Anthony G Letai, Jacob D Jaffe, Piotr Sicinski, Myles Brown, Deborah Dillon, Henry W Long, Franziska Michor, Kornelia Polyak
Triple-negative breast cancer (TNBC) is a heterogeneous disease with limited treatment options. To characterize TNBC heterogeneity, we defined transcriptional, epigenetic, and metabolic subtypes and subtype-driving super-enhancers and transcription factors by combining functional and molecular profiling with computational analyses. Single-cell RNA sequencing revealed relative homogeneity of the major transcriptional subtypes (luminal, basal, and mesenchymal) within samples. We found that mesenchymal TNBCs share features with mesenchymal neuroblastoma and rhabdoid tumors and that the PRRX1 transcription factor is a key driver of these tumors...
December 13, 2023: Cell Reports